PRELIMINARY RESULTS OF DARATUMUMAB, CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIED TREATMENT FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) TRANSPLANT ELIGIBLE (TE) PATIENTS E.Q. Crusoé, M.A. Salvino, S.Q. Silva, H.H.M. Santos, A.S. Santos, A.M. Almeida, L.O. Vieira, C.A. Fonseca, L.F. Lucas, J.S. Leal, M.M. Santos, J.A. Santos, E. Adorno, V.T.M. Hungria, M.G.B. Arruda

DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIFIED TREATMENT FOR TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TE NDMM) PATIENTS EQ Crusoe, J Santos, J Leal, H Santos, A Almeida, L Lucas, M Chaves, V Hungria, M Salvino, MG Arruda

DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE FOR TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TE NDMM) PATIENTS: RESPONSE RATE IMPACTS ON PFS EQ Crusoé, JSLRD Santos, JAD Santos, HHM Santos, AS Santos, LF Lucas, AM Almeida, VT Hungria, MA Salvino, MGB Arruda